CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
Ahead Therapeutics is developing a novel treatment for Type 1 diabetes using liposomes that contain auto-autoantigens. This approach aims to induce immune tolerance and restore insulin-producing cells, potentially offering a long-lasting cure for autoimmune diseases without the side effects of traditional therapies.
Autoimmune diseases (AD) affect 5-10% of the global population and require chronic palliative treatments, resulting in lower quality of life and great costs for society.
Moreover, a steady rise in the incidence of some AD such as Type 1 diabetes (T1D) has been detected worldwide.
Main treatments for T1D are currently based on the continuous administration of exogenous insulin, but none of the 20 existing marketed insulins can achieve a sustained glycaemic level control.
Thus, they cannot fully p…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
